IL-6 (Interleukin 6) Blockade and Heart Rate Corrected QT Interval Prolongation in COVID-19
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Circulation. Arrhythmia and electrophysiology - 13(2020), 9 vom: 04. Sept., Seite e008791 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lazzerini, Pietro Enea [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.09.2020 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1161/CIRCEP.120.008791 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312790104 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312790104 | ||
| 003 | DE-627 | ||
| 005 | 20231225145154.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIRCEP.120.008791 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1042.xml |
| 035 | |a (DE-627)NLM312790104 | ||
| 035 | |a (NLM)32702997 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lazzerini, Pietro Enea |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IL-6 (Interleukin 6) Blockade and Heart Rate Corrected QT Interval Prolongation in COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.09.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a cytokines | |
| 650 | 4 | |a electrocardiography | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a interleukins | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 650 | 7 | |a sarilumab |2 NLM | |
| 650 | 7 | |a NU90V55F8I |2 NLM | |
| 700 | 1 | |a Laghi-Pasini, Franco |e verfasserin |4 aut | |
| 700 | 1 | |a Acampa, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Boutjdir, Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Leopoldo Capecchi, Pier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation. Arrhythmia and electrophysiology |d 2008 |g 13(2020), 9 vom: 04. Sept., Seite e008791 |w (DE-627)NLM184814200 |x 1941-3084 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2020 |g number:9 |g day:04 |g month:09 |g pages:e008791 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/CIRCEP.120.008791 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2020 |e 9 |b 04 |c 09 |h e008791 | ||